Ozurdex may be effective for BRVO prognosis

February 6, 2013

Ozurdex could have a beneficial effect on the visual prognosis in branch retinal vein occlusion (BRVO), reveals a study in Eye.

Ozurdex could have a beneficial effect on the visual prognosis in branch retinal vein occlusion (BRVO), reveals a study in Eye.

A team led by Dr E. Moisseiev, Department of Ophthalmology, Tel Aviv Medical Centre, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, assessed a total of 17 patients who were administered Ozurdex injections as part of the GENEVA study.

The outcome measures included final visual acuity (VA), final retinal thickness by optical coherence tomography, persistence of macular oedema and the occurrence of complications.

It was found retinal thickness reduced significantly in all patients, but 12 patients experienced cataract progression, one had neovascularization and one had vitreous haemorrhage.

BRVO patients demonstrated a more favourable prognosis than CRVO patients. The mean VA of the BRVO patients improved significantly, whereas this was not true for CRVO patients. Based on the results Ozurdex was deemed to have a favourable long-term safety profile and may provide good outcomes for BRVO patients although further study is requried.

For more information on the study please click here.

Related Content:

Articles | Retina